Furthermore, the protein and lipid composition of these dynamic signaling platforms may alter as a result of electrophysiological activity, oxidative damage, changes in lipids such as reduced cholesterol, hypoxia, and other cellular activities, and insults that are known to influence the initiation and/or progression of AD, thus influencing AβO binding and the downstream signaling pathways that are activated. The gene discussed is ABO; the disease is Alzheimer disease.